Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis
H Goldvaser, TA Barnes, B Šeruga… - JNCI: Journal of the …, 2018 - academic.oup.com
Background A number of randomized controlled trials (RCTs) have reported improvement in
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …
Endocrine therapy for early breast cancer: updated review
A Tremont, J Lu, JT Cole - Ochsner Journal, 2017 - ochsnerjournal.org
Background: Although breast cancer is still the second most common cause of cancer-
related deaths, breast cancer mortality has been declining because of advances in the use …
related deaths, breast cancer mortality has been declining because of advances in the use …
[HTML][HTML] De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of …
G Curigliano, HJ Burstein, EP Winer, M Gnant… - Annals of …, 2017 - Elsevier
ABSTRACT The 15th St. Gallen International Breast Cancer Conference 2017 in Vienna,
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …
Austria reviewed substantial new evidence on loco-regional and systemic therapies for early …
Comparison of the performance of 6 prognostic signatures for estrogen receptor–positive breast cancer: a secondary analysis of a randomized clinical trial
Importance Multiple molecular signatures are available for managing estrogen receptor (ER)–
positive breast cancer but with little direct comparative information to guide the patient's …
positive breast cancer but with little direct comparative information to guide the patient's …
Integration of clinical variables for the prediction of late distant recurrence in patients with estrogen receptor–positive breast cancer treated with 5 years of endocrine …
Purpose Estimating risk of late distant recurrence (DR) is an important goal for managing
women with hormone receptor–positive breast cancer after 5 years of endocrine treatment …
women with hormone receptor–positive breast cancer after 5 years of endocrine treatment …
Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial
VCG Tjan-Heijnen, IEG van Hellemond… - The Lancet …, 2017 - thelancet.com
Background The effect of extended adjuvant aromatase inhibition in hormone receptor-
positive breast cancer after sequential endocrine therapy of tamoxifen followed by an …
positive breast cancer after sequential endocrine therapy of tamoxifen followed by an …
Breast cancer treatment-induced cardiotoxicity
S Martel, C Maurer, M Lambertini, N Pondé… - Expert opinion on …, 2017 - Taylor & Francis
Introduction: Breast cancer is the most frequent cancer affecting women worldwide. In every
setting, the majority of women are treated with an evergrowing arsenal of therapeutic agents …
setting, the majority of women are treated with an evergrowing arsenal of therapeutic agents …
Adjuvant endocrine therapy for hormone-positive breast cancer, focusing on ovarian suppression and extended treatment: an update
D Glassman, SUE Hignett, S Rehman… - Anticancer …, 2017 - ar.iiarjournals.org
The benefits of five years of adjuvant endocrine therapy for oestrogen receptor (ER)-positive
early breast cancer are well established. However, recent evidence suggests that extended …
early breast cancer are well established. However, recent evidence suggests that extended …
Extended adjuvant endocrine therapy in early breast cancer: a meta-analysis of published randomized trials
EM Ibrahim, MR Al-Hajeili, AM Bayer, OA Abulkhair… - Medical Oncology, 2017 - Springer
Adjuvant endocrine therapy for 5 years is the standard adjuvant treatment for estrogen
receptor-positive breast cancer while the benefits of extended adjuvant endocrine therapy …
receptor-positive breast cancer while the benefits of extended adjuvant endocrine therapy …
Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically-defined subgroups: a systematic review …
H Goldvaser, I AlGorashi, D Ribnikar, B Seruga… - Cancer treatment …, 2017 - Elsevier
Abstract Background Randomized controlled trials (RCTs) have shown improvements in
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …
breast cancer outcomes from extending treatment with aromatase inhibitors (AIs) beyond the …